Bio-Rad Laboratories (NYSE:BIO – Get Free Report) posted its earnings results on Thursday. The medical research company reported $3.10 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.17, Briefing.com reports. The company had revenue of $681.18 million for the quarter, compared to the consensus estimate of $685.00 million. Bio-Rad Laboratories had a […]
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report)’s stock price gapped up prior to trading on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $328.73, but opened at $350.00. Bio-Rad Laboratories shares last traded at $353.18, with a volume of 85,007 shares changing hands. The medical research […]
Clearstead Advisors LLC decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 35.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120 shares of the medical research company’s stock after selling 67 shares during the period. […]
Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) have been assigned a consensus recommendation of “Buy” from the four analysts that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued a report on the […]
Los Angeles Capital Management LLC decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 74.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,667 shares of the medical research company’s stock after selling 10,614 shares during the quarter. Los Angeles Capital […]